Table 3.
IC50 (μM) | |
---|---|
Kayeassamin I (1) | >100 (37.5)a |
Mammeasin E (2) | 22.6 |
Mammeasin F (3) | >100 (14.9)a |
Mammeasin A (4) | 19.0 |
Mammeasin B (5) | 24.0 |
Mammeasin C (6) | 91.9 |
Mammeasin D (7) | >100 (16.4)a |
Kayeassamin A (8) | >100 (20.2)a |
Kayeassamin E (9) | 33.8 |
Kayeassamin F (10) | 15.9 |
Kayeassamin G (11) | 17.7 |
Surangin B (12) | >100 (38.5)a |
Surangin C (13) | 5.9 |
Mammea A/AA (17) | 19.5 |
Mammea A/AB (18) | >100 (23.3)a |
Mammea A/AC (19) | >100 (41.5)a |
Mammea A/AD (20) | >100 (30.3)a |
Mammea E/BB (22) | 16.8 |
Mammea E/BC (23) | >100 (19.1)a |
Mammea A/AA cyclo D (24) | >100 (38.3)a |
Mammea A/AB cyclo D (25) | >100 (6.7) |
Mammea A/AC cyclo D (26) | >100 (32.0)a |
Mammea B/AB cyclo D (27) | >100 (40.7)a |
Mammea B/AC cyclo D (28) | >100 (27.3)a |
Mammea E/BC cyclo D (29) | >100 (31.9)a |
Deacetylmammea E/AA cyclo D (31) | >100 (37.1)a |
Deacetylmammea E/BB cyclo D (32) | >100 (31.9)a |
Deacetylmammea E/BC cyclo D (33) | >100 (40.8)a |
Mammea A/AA cyclo F (34) | 23.6 |
Mammea A/AC cyclo F (35) | 83.8 |
Finasterideb | 0.12 |
Each value represents the mean ± S.E.M. (N = 3–4).
Values in parentheses present of control of cell viability at 100 μM.
Commercial finasteride was purchased from Sigma-Aldrich Co. LLC (St. Louis, USA).